abs340.txt	loss	of	the	short	arm	of	chromosome	3	(3p)	occurs	early	in	>95%	of	clear	cellrenal	cell	carcinoma	(ccrcc)		nearly	ubiquitous	3p	loss	in	ccrcc	suggestshaploinsufficiency	for	3p	tumor	suppressors	as	early	drivers	of	tumorigenesis		wepreviously	reported	methyltransferase	setd2		which	trimethylates	h3	histones	onlysine	36	(h3k36me3)	and	is	located	in	the	3p	deletion		to	also	trimethylatemicrotubules	on	lysine	40	(αtubk40me3)	during	mitosis		with	αtubk40me3	requiredfor	genomic	stability		we	now	show	that	monoallelic		setd2-deficient	cellsretaining	h3k36me3		but	not	αtubk40me3		exhibit	a	dramatic	increase	in	mitoticdefects	and	micronuclei	count		with	increased	viability	compared	with	biallelicloss		in	setd2-inactivated	human	kidney	cells		rescue	with	a	pathogenic	setd2mutant	deficient	for	microtubule	(αtubk40me3)		but	not	histone	(h3k36me3)methylation		replicated	this	phenotype		genomic	instability	(micronuclei)	wasalso	a	hallmark	of	patient-derived	cells	from	ccrcc		these	data	show	that	thesetd2	tumor	suppressor	displays	a	haploinsufficiency	phenotype	disproportionatelyimpacting	microtubule	methylation	and	serves	as	an	early	driver	of	genomicinstability	significance		loss	of	a	single	allele	of	a	chromatin	modifier	plays	arole	in	promoting	oncogenesis		underscoring	the	growing	relevance	of	tumorsuppressor	haploinsufficiency	in	tumorigenesis		cancer	res		78(12)		3135-46	©2018	aacr	

abs140.txt	human	endogenous	retroviruses	(hervs)	are	remnants	of	exogenous	retroviruses	thathave	integrated	into	the	genome	throughout	evolution		we	developed	acomputational	workflow		hervquant		which	identified	more	than	3	000transcriptionally	active	hervs	within	the	cancer	genome	atlas	(tcga)	pan-cancerrna-seq	database		herv	expression	was	associated	with	clinical	prognosis	inseveral	tumor	types		most	significantly	clear	cell	renal	cell	carcinoma	(ccrcc)	we	explored	two	mechanisms	by	which	herv	expression	may	influence	the	tumorimmune	microenvironment	in	ccrcc		(i)	rig-i-like	signaling	and	(ii)	retroviralantigen	activation	of	adaptive	immunity		we	demonstrated	the	ability	of	hervsignatures	associated	with	these	immune	mechanisms	to	predict	patient	survival	inccrcc		independent	of	clinical	staging	and	molecular	subtyping		we	identifiedpotential	tumor-specific	herv	epitopes	with	evidence	of	translational	activitythrough	the	use	of	a	ccrcc	ribosome	profiling	(ribo-seq)	dataset		validated	theirability	to	bind	hla	in	vitro		and	identified	the	presence	of	mhctetramer-positive	t	cells	against	predicted	epitopes		herv	sequences	identifiedthrough	this	screening	approach	were	significantly	more	highly	expressed	in	ccrcctumors	responsive	to	treatment	with	programmed	death	receptor	1	(pd-1)inhibition		hervquant	provides	insights	into	the	role	of	hervs	within	the	tumorimmune	microenvironment		as	well	as	evidence	that	herv	expression	could	serve	asa	biomarker	for	patient	prognosis	and	response	to	immunotherapy	

abs40.txt	addressing	social	determinants	of	health	(sdoh)	has	been	acknowledged	as	anessential	objective	for	the	promotion	of	both	population	health	and	healthequity		extant	literature	has	identified	seven	potential	areas	of	investment	toaddress	sdoh		investments	in	sexual	and	reproductive	health	and	family	planning	early	learning	and	child	care		education		universal	health	care		as	well	asinvestments	to	reduce	child	poverty		ensure	sustainable	economic	development		andcontrol	health	hazards		the	aim	of	this	paper	is	to	produce	a	'report	card'	oncanada's	success	in	reducing	socioeconomic	and	health	inequities	pertaining	tothese	seven	policy	domains		and	to	assess	how	canadian	trends	compare	to	those	inthe	united	kingdom	(uk)		a	country	with	a	similar	health	and	welfare	system	summarising	evidence	from	published	studies	and	national	statistics		we	foundthat	canada's	best	successes	were	in	reducing	socioeconomic	inequalities	in	earlylearning	and	child	care	and	reproductive	health-specifically	in	improving	equityin	maternal	employment	and	infant	mortality		comparative	data	suggest	thatcanada's	outcomes	in	the	latter	areas	were	like	those	in	the	uk		in	contrast	canada's	least	promising	equity	outcomes	were	in	relation	to	health	hazardcontrol	(specifically		tobacco)	and	child	poverty		though	canada	and	the	ukobserved	similar	inequities	in	smoking		canada's	slow	upward	trend	in	childpoverty	prevalence	is	distinct	from	the	uk's	small	but	steady	reduction	of	childpoverty		this	divergence	from	the	uk's	trends	indicates	that	alternativeinvestment	types	and	levels	may	be	needed	in	canada	to	achieve	similar	outcomesto	those	in	the	uk	

abs240.txt	importance		preferential	delivery	of	docetaxel	to	tumors	by	prostate-specificmembrane	antigen	(psma)-targeted	nanoparticles	is	clinically	effective		and	theselective	reduction	of	psma-positive	circulating	tumor	cells	(ctcs)	aftertreatment	has	implications	for	patient	selection	and	disease	monitoring	objective		to	determine	the	safety	and	efficacy	of	bind-014		a	psma-directeddocetaxel-containing	nanoparticle		in	patients	with	metastaticcastration-resistant	prostate	cancer	(mcrpc)	design		setting		and	participants		a	multicenter	open-label		phase	2	clinicaltrial	of	42	chemotherapy-naive	patients	with	progressing	mcrpc	after	treatmentwith	abiraterone	acetate	and/or	enzalutamide	was	conducted	from	june	24		2013		tojune	10		2016	intervention		treatment	with	bind-014	at	a	dosage	of	60	mg/m2	was	givenintravenously	on	day	1	of	21-day	cycles	in	combination	with	prednisone	untildisease	progression	or	unacceptable	toxic	effects	occurred	main	outcomes	and	measures		the	primary	end	point	was	radiographicprogression-free	survival	according	to	prostate	cancer	working	group	2recommendations	and	response	evaluation	criteria	in	solid	tumors		version	1	1	secondary	end	points	included	prostate-specific	antigen	(psa)	response	(≥50%reduction	from	baseline)	and	changes	in	ctc	number	(from	≥5	to	<5	cells	per	7	5ml	of	blood)	(cellsearch)		changes	in	ctc	number	based	on	psma	expression	levelson	ctcs	were	also	evaluated	(epic	sciences)	results		among	the	42	patients	(81%	white)		the	median	age	was	66	(range		50-85)years		and	median	number	of	doses	received	was	6	(range		1-21)		a	psa	responsewas	observed	in	12	of	40	patients	(30%		95%	ci		18%-45%)		measurable	diseaseresponse	in	6	of	19	(32%	[95%	ci		15%-54%])		and	ctc	conversions	in	13	of	26(50%		95%	ci		32%-68%)		median	radiographic	progression-free	survival	was	9	9(95%	ci		7	1-12	6)	months		with	use	of	the	epic	sciences	non-epcam-based	ctcdetection	platform		ctcs	were	detected	in	16	of	18	patients	(89%)		11	of	18	(61%)had	ctcs	with	psma	expression	above	the	analytical	threshold	level	(psmapositive)	at	baseline	(range		0	4-72	4	ctcs/ml)		after	treatment		psma-positivectcs	were	preferentially	reduced		treatment-related	adverse	events	included	grade1	or	2	fatigue	(29	of	42	patients	[69%])		nausea	(23	[55%])		neuropathy	(14[33%])		and	neutropenic	fever	(1	[2%])	conclusions	and	relevance		these	findings	suggest	that	treatment	with	bind-014	isactive	and	well	tolerated	in	patients	with	chemotherapy-naive	mcrpc		antitumoractivity	may	be	related	to	psma	expression	levels	on	ctcs		which	suggests	thatpatients	who	are	likely	to	benefit	from	this	treatment	can	be	identified	beforetreatment	is	initiated	trial	registration		clinicaltrials	gov	identifier		nct01812746	

